ctDNA-guided adjuvant treatment after radical-intent treatment of metastatic spread from colorectal cancer-the first interim results from the OPTIMISE study.
Louise Bach CallesenTorben Frøstrup HansenRikke Fredslund AndersenNiels PallisgaardStine KramerSven SchlanderSøren Rafael RafaelsenAnders Kindberg BoysenLars Henrik JensenAnders JakobsenKaren-Lise Garm SpindlerPublished in: Acta oncologica (Stockholm, Sweden) (2023)
The study was proven to be feasible and continues in the planned large-scale phase II trial. Results from the OPTIMISE study will potentially optimize the adjuvant treatment of patients undergoing radical-intent treatment of mCRC, thereby improving survival and reducing chemotherapy-related toxicity.